Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) hit a new 52-week high during trading on Tuesday . The company traded as high as $3.89 and last traded at $3.88, with a volume of 2500599 ...

The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic ...

Xeris has three commercially available products: Recorlev, for the treatment of endogenous Cushing’s syndrome; Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and ...

In the US, Baqsimi is now competing head-to-head with Xeris’ Gvoke, pre-filled syringe and pen injector formulations of glucagon that don’t require the mixing steps and can be used in patients ...

Another drugs that may be used off-label for GHI include Xeris' Gvoke brand of glucagon in pre-filled syringe and pen injector formulations, which was approved in 2019 as a hypoglycaemia rescue ...

Just open the Gemini app, tap your profile avatar in the top-right corner of the screen and select “Extensions.” From there, ...

With Grok-3, xAI aims to outsmart the competition. We pit it against GPT-4o, Gemini, DeepSeek, and Claude 3.5 Sonnet to see ...

But did you know that the type of toothbrush you use can impact how clean your teeth are getting? Electric toothbrushes are becoming more affordable and easy to find, and they have several benefits.

Learn about the performance of Grok 3, Elon Musk’s AI with real-time, multimodal functions, and how it compares to ChatGPT ...

Musk's artificial intelligence startup, xAI, introduced its latest AI model, Grok 3, on Tuesday, claiming it surpasses ...

January 29, 2025 Introducing "Study Break" January 29, 2025 • Welcome to How To Do Everything's "study break". This Friday at 12 PM CT, we will drop a Zoom link in this Google document. The ...

xAI is promoting Grok 3 as the best model on the market, claiming it surpassed competitors from OpenAI, Google, Anthropic, ...